Article
A low dose of naloxone mitigates autoimmune hepatitis by regulating TLR4/NF-κB and Nrf2/HO-1 signaling pathways
2023-05-04
Abstract excerpt
<title>Abstract</title> <p>Naloxone is a non-selective opiate receptor antagonist that is mainly used in the management of opiate addiction. Previously, naloxone has been shown to have anti-inflammatory and antioxidant properties. A popular and well-known animal model of autoimmune hepatitis that closely matches the pathogenic changes that take place in humans is the Concanavalin A (Con A) model. The present stud...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 06c81aa1-8db0-5831-8493-b3d7dd92f551
- DOI
- 10.21203/rs.3.rs-2873574/v1
